Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Open access

Abstract

Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B cells.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00889-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 32 references

Cited by

See all 337

Metadata

Authors
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., Elliott, B., DeMarco, D., Azaryan, A., Chiu, C., Li, T., Chen, K.-M., Ahmadi, T., & Lugtenburg, P. J.
Affiliations
  • Rigshospitalet (DK)
  • University Medical Center Utrecht (NL)
  • Vejle Sygehus (DK)
  • Cancer Research UK (GB)
  • University of Manchester (GB)
  • Hovon (NL)
  • University of Plymouth (GB)
  • Royal Marsden NHS Foundation Trust (GB)
  • Genmab (Denmark) (DK)
  • Genmab (United States) (US)
  • Erasmus MC Cancer Institute (NL)
Corresponding author
Hutchings, Martin
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-09
Volume
398
Issue
10306
Pages
1157-1169
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3198713553
Cited by
337
References
32
Citations by year
2026: 38 · 2025: 49 · 2024: 88 · 2023: 90 · 2022: 69 · 2021: 3
FWCI
41.62
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc-nd)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
AbbVie
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
epcoritamab, bispecific antibodies, relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, subcutaneous administration, dose escalation, maximum tolerated dose, recommended phase 2 dose, cytokine release syndrome, fever, pharmacokinetics, T cell cytotoxicity
MeSH terms
Aged, Europe, Female, United Kingdom, Humans, Injections, Subcutaneous, Lymphoma, Non-Hodgkin, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A second model labelled each claim on 2026-10-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00889-8
The paper
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., Elliott, B., DeMarco, D., Azaryan, A., Chiu, C., Li, T., Chen, K.-M., Ahmadi, T., & Lugtenburg, P. J. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. https://doi.org/10.1016/s0140-6736(21)00889-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.